Vericiguat is a pyrazolopyridine that is 5-fluoro-1H-pyrazolo[3,4-b]pyridine in which the amino hydrogen at position 1 has been substituted by a 2-fluorobenzyl group and the hydrogen at position 3 has been substituted by a 4,6-diamino-5-[(methoxycarbonyl)amino]pyrimidin-2-yl group. It is a soluble guanylate cyclase stimulator which is used for treatment of chronic heart failure. It has a role as a soluble guanylate cyclase activator, a vasodilator agent and an antihypertensive agent. It is an aminopyrimidine, a pyrazolopyridine, a carbamate ester and an organofluorine compound.

Vericiguat is under investigation in clinical trial NCT02861534 (A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)).

Vericiguat is a Soluble Guanylate Cyclase Stimulator. The mechanism of action of vericiguat is as a Guanylate Cyclase Stimulator.

Vericiguat is a medication used to manage and treat heart failure with reduced ejection fraction (HFrEF). It is useful for chronic worsening heart failure, recently decompensated heart failure. Vericiguat does not prolong survival but prevents rehospitalization. This activity outlines the indications, mechanism of action, dose, and mode of administration by the interprofessional team, adverse effects, contraindications, and several trials to support the evidence of the drug's usefulness in HFrEF.